RAP-219 Clears Phase 2 With a Modest, Tolerable Mania Signal
Rapport Therapeutics reported that RAP-219 met the primary endpoint in a 253-patient randomized Phase 2 trial in acute bipolar mania. The TARPγ8-selective AMPA receptor negative allosteric modulator produced a 3.1-point placebo-adjusted improvement on the…
